Name | BI-653048 |
---|
Description | An oral glucocorticoid agonist for the treatment of rheumatoid arthritis. Rheumatoid Arthritis Phase 1 Clinical |
---|---|
Related Catalog | |
Target |
CYP1A2:50 μM (IC50) CYP2D6:41 μM (IC50) CYP2C9:12 μM (IC50) CYP2C19:9 μM (IC50) CYP3A4:8 μM (IC50) |
In Vitro | BI 653048 phosphate exhibits an improved drug-like properties, inhibits CP1A2 ,CYP2D6 ,CYP2C9, CYP2C19 and CYP3A4 with IC50 values of 50 µM, 41 µM, 12 µM, 9 µM,and 8 µM, respectively[2]. BI 653048 phosphate reduces affinity for the hERG ion channel with an IC50>30 μM in recombinant HEK293 cells expressing the human ERG potassium channel[2]. BI 653048 phosphate inhibits TNF-stimulated IL-6 production in mouse RAW cells with an IC50 value of 100 nM[2]. |
In Vivo | BI 653048 phosphate (oral administration; 3, 10, and 30 mg/kg) at 3 mg/kg has nonsignificant decreases for all measured histology parameters (ankle inflammation, pannus formation, cartilage damage, and bone resorption), Mid-dose (10 mg/kg) treatment significantly decreases pannus and bone resorption (33%) as well as summed scores (27%), while at high dose (30 mg/kg), all parameters are significantly decreased (87–96%). The ED50 value for the summed scores is 14 mg/kg[2]. Animal Model: Mice[2] Dosage: 3, 10, and 30 mg/kg Administration: Oral administration Result: Exhibited significant decreases for all measured histology parameters at high doses. |
References |
[3]. Montse Llinas-Brunet, et al. Latest bibliographic data on file with the International Bureau |
Molecular Formula | C23H28F4N3O8PS |
---|---|
Molecular Weight | 613.517 |